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Abstract 31 
Flavobacterium psychrophilum is one of the most important pathogens affecting cultured 32 
rainbow trout (O. mykiss). Recent information from UK salmonid farms showed country-wide 33 
distribution of genetically and serologically divergent clones which has hampered the 34 
development of a vaccine for Rainbow Trout Fry Syndrome. The current study assessed the 35 
efficacy of an injectable polyvalent vaccine containing formalin-inactivated F. psychrophilum 36 
in rainbow trout. The vaccine was formulated with an oil adjuvant (Montanide ISA 760VG) 37 
or formalin killed cells alone. Duplicate groups of trout (60 ± 13 g) were given phosphate 38 
buffered saline or vaccine formulated with Montanide by intraperitoneal (i.p.) injection and 39 
challenged by intramuscular (i.m.) injection with a homologous and a heterologous isolate of 40 
F. psychrophilum at 525 degree days post-vaccination (dd pv). Significant protection was 41 
achieved in vaccinated fish (p=0.0001, RPS 76% homologous, 88% heterologous). Efficacy 42 
of the adjuvanted vaccine was also demonstrated by heterologous challenge at 1155 dd pv 43 
resulting in 100% protection, whereas survival in the un-adjuvanted group was not 44 
significantly different from control fish. Levels of specific antibody at 1155 dd pv, as 45 
measured by ELISA, were significantly higher in the fish vaccinated with adjuvant when 46 
compared with unvaccinated fish. 47 
 48 
 49 
1 Introduction 50 
Rainbow trout fry syndrome (RTFS), caused by F. psychrophilum, is a major cause of 51 
mortality in salmonid aquaculture and other species worldwide (Barnes, 2011). F. 52 
psychrophilum is a highly heterogeneous pathogen, and as a result, only one commercial 53 
vaccine (ALPHA JECT® IPNV-Flavo, a killed injectable vaccine licensed in Chile) is 54 
  
 
available to control this problematic disease (Gómez, Méndez, Cascales, & Guijarro, 2014; 55 
Wahli & Madsen, 2018). Treatment is still largely limited to the use of antibiotics, which has 56 
led to increased levels of antibiotic resistance (Henríquez-Núñez, Evrard, Kronvall, & 57 
Avendaño-Herrera, 2012; Verner-Jeffreys & Taylor, 2015), highlighting the urgent need for 58 
preventative measures for control of RTFS. The rainbow trout (O. mykiss) industry in the UK 59 
is critically dependent on the continued clinical efficacy of a single antimicrobial agent, 60 
florfenicol (Verner-Jeffreys & Taylor, 2015), highlighting the need for the development of a 61 
cross-protective vaccine. As outbreaks in larger trout (50-500 g) have recently been reported 62 
in the UK (Iglesias, 2017) causing reduced appetite, lesions and requiring treatment with 63 
antibiotics, there is also a need for a vaccine to provide longer term protection i.e. over the 64 
whole production cycle. 65 
A previous study in our laboratory characterised F. psychrophilum by genotyping and 66 
serotyping a large collection of isolates gathered from clinical outbreaks in rainbow trout, 67 
Atlantic salmon (Salmo salar) and coho salmon (Onchorynchus kisutch) (Ngo et al., 2017). 68 
The work revealed high heterogeneity in the strains of F. psychrophilum and highlighted the 69 
need for such studies to enable selection of vaccine candidates with the potential for 70 
protection of both trout and salmon. The vaccine developed from these studies has been 71 
applied to salmon via injection and trout fry by immersion vaccination, resulting in excellent 72 
levels of protection (Hoare et al., 2017; Hoare, Ngo, Bartie, & Adams, 2017). As immersion 73 
vaccines are currently lacking mucosal adjuvants the protection afforded by this method 74 
would only cover the early life stages. Therefore an adjuvanted vaccine delivered by 75 
intraperitoneal (i.p.) injection, would be the optimal method to vaccinate fish at later stages in 76 
the production cycle. Oil adjuvanted vaccines are known to be strong inducers of local 77 
  
 
inflammatory reactions followed by a specific systemic immune response (Fredriksen et al., 78 
2013).  79 
The current study was performed to assess the efficacy of a polyvalent, whole cell injectable 80 
vaccine containing formalin-inactivated F. psychrophilum, with and without adjuvant 81 
(mineral oil, Montanide™) to induce protective immunity in rainbow trout (60 g) against the 82 
pathogen. Protection against a homologous and a heterologous strain was investigated in trout 83 
at 525 dd and efficacy of the vaccine against a heterologous isolate at 1155 dd (nearly twice 84 
that recommended by most vaccine manufacturers for induction of immunity to bacterial 85 
antigens). Immune responses in vaccinated and unvaccinated trout were investigated pre-86 
challenge by ELISA and Western blot. 87 
 88 
2 Materials and Methods 89 
2.1 Rainbow trout  90 
Rainbow trout eggs were supplied by AquaGen (Norway) and transported on ice to the 91 
aquarium at the Institute of Aquaculture, University of Stirling. On arrival, the eggs were 92 
subjected to iodophor surface disinfection according to the manufacturer’s instructions 93 
(Buffodine, Evans Vanodine, UK). Five replicates of 10 eggs were removed and confirmed to 94 
be F. psychrophilum-free using a nested PCR that targets the 16S rRNA gene (Ngo et al., 95 
2017; Toyama, Kita-Tsukamoto, & Wakabayashi, 1994). The eggs were maintained in flow-96 
through de-chlorinated tap water at 10ºC until hatch, and thereafter maintained in a 100 L 97 
flow-through tank (5 L min-1). Fry were fed to satiation daily (Inicio feed, 1.1 mm, BioMar, 98 
UK). All experimental procedures with live fish were carried out in accordance with the UK 99 
Animals (Scientific Procedures) Act, 1986 and associated guidelines (EU Directive 100 
2010/63/EU) and were approved by the Ethics Committee of the University of Stirling.  101 
 102 
  
 
2.2 Preparation of formalin inactivated bacteria  103 
Two isolates of F. psychrophilum recovered from trout and one recovered from Atlantic 104 
salmon in the UK in 2013 were used to make a formalin killed whole cell vaccine (FKC) 105 
(AVU-1T/13, serotype Fd; AVU-2T/13, serotype Th; and AVU-3S/13, serotype  FpT; ) as 106 
described previously (Hoare et al., 2017).  The three cultures were mixed in equal parts to 107 
form the whole cell vaccine at a final concentration of 1 × 109 colony forming units (CFU) 108 
mL−1. 109 
 110 
2.3 Preparation of vaccine formulations and vaccination 111 
The formalin-inactivated vaccine prepared above, was emulsified with Montanide 760VG 112 
(Seppic, France) (Montanide70:FKC30) and stored at 4 ºC. Stability of the emulsion was 113 
examined macro and microscopically for a 7 day period following emulsification. 114 
Fish (60 g ± 13) were randomly separated into 100 L flow-through tanks with aeration at 115 
15ºC. The experimental design of the vaccination trials is summarised in Table 1. As previous 116 
studies have shown no protection after challenge when adjuvant alone is administered 117 
(Fredriksen et al., 2013), an adjuvant-alone group was excluded from this study. Fish were 118 
anaesthetised with benzocaine (Sigma, 0.004%) and vaccinated by i.p. injection (50 µl/fish). 119 
Control groups were injected i.p. with 50 µl/fish of sterile phosphate buffered saline (PBS). 120 
Prior to challenge (525 dd and 1155 dd pv) fish were anaesthetised with benzocaine (as 121 
above) and blood was sampled from the caudal vein using a 23 G needle and syringe from 122 
three fish per duplicate group (n= 6) stored overnight at 4ºC, centrifuged for 5 min at 3000 x g 123 
for collection of serum, and stored at -20ºC until analysis.  124 
 125 
2.4 Experimental infection of vaccinated fish 126 
  
 
Dose response studies were conducted to determine the lethal dose 60 % (LD60) for each 127 
isolate (data not shown). Challenge was conducted with both a homologous strain (AVU-128 
2T13; 1.3 x 107 colony forming units (CFU/fish) and a heterologous strain of F. 129 
psychrophilum (AVU-1T/07; 3.6 x 107 CFU/fish) at 525 dd pv, and only with a heterologous 130 
strain (AVU-1T/07; 1.7 x 107 CFU/fish) at 1155 dd pv. The fish were maintained as above 131 
and monitored for 21 days post infection (dpi). Moribund fish or mortalities were removed 132 
and sampled by streaking head kidney, spleen and any lesions onto Modiﬁed Veggietone 133 
(MV) medium [veggitones GMO-free soya peptone (Oxoid, UK), 5gL −1; yeast extract 134 
(Oxoid, UK), 0.5 g L−1; magnesium sulphate heptahydrate (Fisher chemicals, UK), 0.5 g 135 
L−1; anhydrous calcium chloride (BHD), 0.2 g L−1; dextrose (Oxoid, UK), 2 g L−1; agar 136 
(solid medium; Oxoid, UK), 15 g L−1; pH 7.3] to confirm specific mortality. A sub-sample of 137 
colonies recovered was screened with a nested PCR (Ngo et al., 2017; Toyama et al., 1994), 138 
to confirm re-isolation of F. psychrophilum from the fish.  139 
 140 
2.5 ELISA for detection of specific IgM in serum 141 
Enzyme-linked immunosorbent assay (ELISA) was used to assess specific IgM titres to F. 142 
psychrophilum in serum according to (Hoare et al., 2017). The trout F. psychrophilum vaccine 143 
isolates were used to coat the ELISA plates (Immulon 4 HBX, UK) at 1 x108 CFU/mL in PBS 144 
and incubated overnight at 4°C. The dilution of ﬁsh serum used was optimised by ﬁrst 145 
titrating sera from each group (1:32 to 1:1024). Fish sera samples at the optimised dilution of 146 
1:64 in PBS were added to the wells (100 μl/well) in duplicate and incubated overnight at 147 
4°C. The absorbance was read on a BioTek HT Synergy spectrophotometer at 450 nm.  148 
 149 
2.6 Agglutination assay 150 
  
 
Sera collected from each group at 1155 dd pv were serially diluted two-fold in PBS and 20 μl 151 
added to each well of a round bottom plate (Nunc™). A 20 μl sample of the homologous 152 
strain (AVU-2T13, 2 x108 CFU/mL, formalin-killed) was then added to each well and the 153 
plates were incubated overnight at room temperature. Agglutination was observed under 154 
100X using an inverted microscope (Olympus CK40). The agglutination titre was calculated 155 
as the reciprocal of the highest dilution of serum showing complete agglutination of the 156 
bacteria. 157 
 158 
2.7 SDS-PAGE and Western blotting 159 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  160 
Suspensions of the F. psychrophilum vaccine and challenge strains were aliquoted into 1.5 ml 161 
micro-centrifuge tubes (1 ml of 2 x 108 CFU/mL), and centrifuged for 15 min at 3000 × g. 162 
Bacterial pellets were prepared and applied to a 12% polyacrylamide gel (Bio-Rad) gel 163 
according to [7]. Gels were stained with Coomassie Brilliant Blue (Bio-Rad) or subjected to 164 
Western blotting. Bacterial components separated by SDS-PAGE as described above, were 165 
transferred onto nitrocellulose membranes and incubated with serum taken at 1155 dd pv 166 
according to [7].  167 
 168 
2.8 Statistical Analysis 169 
Relative percentage survival (RPS) was calculated at 21 days post-challenge. Kaplan-Meier 170 
survival curves were generated and the log-rank test was used to compare the survival curves 171 
for the vaccinated fish and unvaccinated fish (E.L. Kaplan, 1958; Peto et al., 1977). Where 172 
there was a significant difference in mortality between replicate tanks statistical analysis was 173 
  
 
run on individual tanks. The relative percent survival (RPS) of this trial was calculated using 174 
the following equation (Amend, 1981): 175 
 176 
RPS = [1 – 
average % mortality of vaccinated fish 
] x 100 
average % mortality of unvaccinated fish 
 177 
Specific antibody levels were analysed by one-way ANOVA followed by Welch’s test.  178 
 179 
3. Results 180 
3.1 Vaccine Efficacy 181 
525 dd pv: The percentage survival of the sham-vaccinated group administered PBS and 182 
challenged with the homologous strain was 40% and with the heterologous strain was 43%. 183 
The vaccinated group had significantly higher survival compared with the unvaccinated 184 
control group following homologous challenge (p = 0.0001, Figure 1 a). Following 185 
heterologous challenge there was a significant difference between control tanks so individual 186 
tanks were compared and control tank 2 had significantly higher survival compared with 187 
vaccinated tanks (p = 0.0001, Figure 1 b). The vaccine formulation containing FKC combined 188 
with Montanide ISA 760VG gave high levels of protection against both the homologous and 189 
the heterologous strains of F. psychrophilum (RPS of 76% and 88% respectively). 190 
Figure 1. here 191 
1155 dd pv: Percentage survival in the sham-vaccinated trout injected with PBS was 29% and 192 
trout vaccinated with FKC combined with Montanide ISA 760VG had significantly higher 193 
survival compared with the unvaccinated controls, RPS of 100% (p = 0.0001, Figure 2). The 194 
vaccine formulation with FKC without adjuvant had a RPS of 25%; survival in this group was 195 
  
 
not significantly different from the control group. Lesions at the challenge injection site were 196 
evident in all unvaccinated fish, approximately 10% of FKC vaccinated fish and were 197 
completely absent from fish vaccinated with FKC and adjuvant. 198 
Figure 2. here 199 
 200 
3.2 Nested PCR for detection of F. psychrophilum 201 
PCR products specific for F. psychrophilum (1080 bp) were detected in moribund and dead 202 
fish sampled during the challenge.  Conversely, the eggs tested negative by PCR 203 
(Supplementary Figure 1).  204 
   205 
3.3 Specific antibody response  206 
Levels of specific antibody at 1155 dd pv, as measured by ELISA against both trout vaccine 207 
strains, were significantly higher in the fish vaccinated with adjuvant when compared with 208 
unvaccinated fish (AVU 1T/13 p = 0.01, AVU 2T/13 p < 0.05) (Figure 3. a, b). Fish 209 
vaccinated with FKC alone had higher antibody levels than those of the control group, but this 210 
was not significant.   211 
Figure 3 here 212 
The specific IgM response of trout to vaccination was also measured by agglutination at 1155 213 
dd pv against the homologous isolate (AVU-2T/13). The unvaccinated group and the group 214 
vaccinated with FKC alone had low titres of 8, whereas the group vaccinated with FKC and 215 
Montanide exhibited a significantly higher average titre of 144 (n= 4, p = 0.04) (Table 2).  216 
 217 
3.4 SDS-PAGE and Western blot 218 
Distinct bands ranging from 10-100 kDa were evident in the SDS-PAGE profiles of the F. 219 
psychrophilum strains used to prepare the polyvalent vaccine (and a heterologous strain AVU-220 
  
 
1T/07) following staining of gels with Coomassie (Figure 4a). The banding profiles of the 221 
strains were similar with a slightly lower weight band occurring in the heterologous strain 222 
between 20-25 kDa. In Western blotting, stronger staining was evident when F. 223 
psychrophilum isolates were screened with serum from the fish vaccinated with FKC and 224 
Montanide (Figure 4b (iii)) compared to that seen with serum of unvaccinated (Figure 4b (i)) 225 
or FKC only vaccinated fish (Figure 4b (ii)).  A prominent band staining strongly between 20-226 
25 kDa for all the F. pychrophilum strains tested was only observed in the blot using sera 227 
from fish vaccinated with FKC and adjuvant. In addition, a region of higher molecular mass 228 
antigens above 75 kDa were recognised by sera from FKC only and FKC and Montanide 229 
vaccinated fish, with stronger staining observed in fish vaccinated with adjuvant. 230 
 231 
 Figure 4 a, b. here 232 
 233 
4. Discussion 234 
Rainbow Trout Fry Syndrome affects juvenile rainbow trout: however recently outbreaks are 235 
occurring in larger fish (50 g+) in the UK (Iglesias, 2017). Therefore, the development of a 236 
vaccine to provide long term protection is needed. The polyvalent vaccine developed against 237 
F. psychrophilum in this study provided significant protection against homologous and 238 
heterologous challenge when administered to rainbow trout by i.p. injection (RPS 76-100%). 239 
The success of many injectable vaccines used in aquaculture has been attributed to the 240 
inclusion of adjuvants (Tafalla, Bøgwald, & Dalmo, 2013). Adjuvants are substances which 241 
enhance the immune response to an antigen (Awate, Babiuk, & Mutwiri, 2013) and one of the 242 
most effective adjuvants used in aquaculture is mineral oil (Rømer Villumsen, Koppang, & 243 
Raida, 2015). The present study clearly demonstrated the enhanced efficacy of the vaccine 244 
against F. psychrophilum when the bacterin was administered with an oil adjuvant 245 
  
 
(Montanide™) providing protection with no mortality or development of lesions following 246 
challenge at 1155 dd pv.  247 
Previous studies using inactivated F. psychrophilum in conjunction with oil adjuvants have 248 
demonstrated protection, usually associated with increased levels of specific IgM in the serum 249 
of vaccinated fish (Fredriksen et al., 2013; Hoare et al., 2017; Högfors, Pullinen, Madetoja, & 250 
Wiklund, 2008; Madetoja et al., 2006). The protection in the current study appears to be at 251 
least partly mediated by specific serum antibodies (IgM) as shown by ELISA, agglutination 252 
and Western blotting. Serum antibodies from fish vaccinated with the polyvalent vaccine 253 
recognised a heterologous strain of F. psychrophilum by Western blotting. A significantly 254 
stronger reaction was observed in the Western blot when sera from fish vaccinated with 255 
adjuvant was applied with bands staining between 20-25 kDa not observed in blots incubated 256 
with un-adjuvanted sera. An additional region >75 kDa was recognised by sera from both 257 
groups of vaccinated fish with stronger staining in the adjuvanted group. These two regions 258 
appear to be the targets of specific antibodies following vaccination. 259 
Previous studies have identified different molecular weight fractions (18–28, 41–49, and 70–260 
100 kDa) as immunogenic molecules of F. psychrophilum by Western blotting, using 261 
convalescent rainbow trout serum (Crump, Perry, Clouthier, & Kay, 2001; Högfors et al., 262 
2008; Benjamin R. LaFrentz, Lindstrom, LaPatra, Call, & Cain, 2007). These proteins have 263 
potential to be the basis for a recombinant vaccine to provide cross-protection against F. 264 
psychrophilum. One such study, using convalescent rainbow trout serum, found an immuno-265 
reactive proteinase K-resistant band with an apparent molecular mass of 17 kDa (Crump et 266 
al., 2001) and suggested the highly immuno-reactive band is likely to be the predominant 267 
component of the thick slime layer seen on the surface of these bacteria, possibly LPS. 268 
Whereas, the high molecular weight fractions are suggested to be part of the glycocalyx of F. 269 
  
 
psychrophilum (Benjamin R. LaFrentz et al., 2007). Further studies are needed to assess the 270 
characteristics of the immunogenic band between 20-25 kDa observed in the present study 271 
with regard to a potential recombinant vaccine target which could be cross-protective. Trials 272 
to date that have assessed the efficacy of fractions to protect trout against laboratory challenge 273 
have shown whole cell formulations to provide greater or equal protection (Aoki, Kondo, 274 
Nakatsuka, Kawai, & Oshima, 2007; Högfors et al., 2008; B R LaFrentz, LaPatra, Jones, & 275 
Cain, 2004; Rahman et al., 2002). Studies such as on the potential of the outer membrane 276 
fraction and membrane vesicle rich supernatant from the stationary phase culture supernatants 277 
of F. psychrophilum have been shown to induce protective immunity in rainbow trout and ayu 278 
(Plecoglossus altivelis) (Aoki et al., 2007; Rahman et al., 2002), however both were less 279 
effective than whole cell formulations. In the present study, the combination of FKC of three 280 
strains of F. psychrophilum and an oil adjuvant induced protection (up to 1155 dd) against a 281 
heterologous strain of F. psychrophilum in rainbow trout. Further large-scale studies, are 282 
needed to determine the efficacy of the developed vaccine against a range of heterologous 283 
strains from different geographical regions. In addition, studies on the innate and cellular 284 
immune response could provide more insight into the mechanisms of protection provided by 285 
the adjuvanted vaccine. 286 
 287 
Conclusions 288 
The adjuvanted, polyvalent vaccine tested in this study gave excellent protection in rainbow 289 
trout (RPS of 100 %) against a heterologous strain of F. psychrophilum. The protection 290 
correlated with systemic IgM responses as observed by ELISA, agglutination and Western 291 
blotting. 292 
 293 
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Table 1. Experimental design of vaccination trials.  382 
Degree days 
post-vaccination 
Groups No. Fish 
(replicate 
tanks) 
Innoculum 
(µl i.p.) 
Challenge strain i.m. 
(Dose:CFU/fish) 
525 Control (unvaccinated) 15 (2) 50 µl PBS Homologous AVU-2T13 
(1.3 x 107) 
Vaccine + Montanide 15 (2) 50 µl FKC:Montanide 
 
Homologous AVU-2T13 
(1.3 x 107) 
Control (unvaccinated) 15 (2) 50 µl PBS Heterologous AVU-1T/07 
(3.6 x 107) 
Vaccine + Montanide 15 (2) 50 µl FKC:Montanide 
 
Heterologous AVU-1T/07 
(3.6 x 107) 
1155 Control (unvaccinated) 14 (2) 50 µl PBS  
Heterologous AVU-1T/07 
(1.7 x 107) 
Vaccine (FKC) 14 (2) 50 µl FKC Heterologous AVU-1T/07 
(1.7 x 107) 
Vaccine 
& Montanide 
14 (2) 50 µl FKC:Montanide Heterologous AVU-1T/07 
(1.7 x 107) 
 
 383 
PBS: phosphate buffered saline; FKC: formalin-killed cells; i.p.: intra-peritoneal; i.m.: intra-muscular, CFU: 384 
colony forming units 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
  
 
 397 
 398 
 399 
Table 2.  Agglutination titre of serum from trout unvaccinated (injected with PBS) and 400 
vaccinated (injected with FKC, or FKC emulsified with Montanide) at 1155 degree days 401 
post-vaccination. 402 
Fish no. Unvaccinated FKC FKC:Montanide 
1 <8 <8 128 
2 <8 <8 64 
3 <8   8 256 
4 <8 <8 128 
   FKC: formalin-killed cells 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
  
 
Figure 1. Percentage survival of rainbow trout vaccinated by intraperitoneal injection with Flavobacterium 421 
psychrophilum-formalin killed cells (FKC) adjuvanted with Montanide ISA 760VG (FKC and Montanide) and 422 
challenged at 525 degree days post-vaccination (dd pv) by intramuscular injection with (A) a homologous strain 423 
of F. psychrophilum (RPS 76%); (B) a heterologous strain of F. psychrophilum (RPS 88%). Controls were given 424 
sterile phosphate buffered saline by intraperitoneal injection. The survival rates from each replicate tank 425 
following challenge are presented (n = 15; p = 0.0001). 426 
 427 
Figure 2. Percentage survival of rainbow trout vaccinated by intraperitoneal injection with Flavobacterium 428 
psychrophilum formalin killed cells (FKC) with and without adjuvant (Montanide ISA 760VG) and challenged 429 
at 1155 degree days post vaccination (dd pv) by intramuscular injection with a heterologous strain of F. 430 
psychrophilum. FKC only (RPS 25%); FKC & Montanide (RPS 100%). Control fish received sterile phosphate 431 
buffered saline by intraperitoneal injection. The survival rates from each replicate tank following challenge are 432 
presented (n = 14; p = 0.0001). 433 
 434 
Figure 3. Specific antibody (IgM) levels to F. psychrophilum in vaccinated rainbow trout at 1155 days post 435 
vaccination. (A) to homologous strain AVU-2T/13; (B) to homologous strain AVU-1T/13. Antibody levels were 436 
significantly higher in the fish vaccinated with adjuvant when compared with unvaccinated fish [AVU 1T/13 p = 437 
0.01, AVU 2T/13 p < 0.05]. Mean values are shown as blue dots. Groups that do not share a letter are 438 
significantly different, (n = 6).  439 
 440 
Figure 4. SDS-PAGE of Flavobacterim psychrophilum strains. (a) Whole cell lysates from vaccine strains (Lane 441 
1: AVU-1T/13, Lane 2: AVU-2T/13, Lane 3: AVU-3S/13) and a heterologous strain (Lane 4: 171/07) were 442 
separated by SDS-PAGE and stained with Coomassie stain.  Arrows indicate high intensity bands at 10-15, 20, 443 
37-50, 100 and 150-250 kDa.  (b) Western blot analysis of a heterologous strain (Lane 1:171/07) and vaccine 444 
strains (Lane 2: AVU-1T/13, Lane 3: AVU-2T/13, Lane 4: AVU-3S/13). Whole cell lysates were separated by 445 
SDS-PAGE, blotted onto nitrocellulose and reacted with serum from (i) unvaccinated (control) fish, (ii) FKC 446 
vaccinated fish or (iii) FKC & Montanide vaccinated fish. Serum was a pool from two fish from each treatment 447 
group, with a titre of 512, taken 11 wpv. Arrows indicate high intensity bands between 20-25 kDa. Molecular 448 
mass standards (kDa) are indicated on the left.  449 
  
 
Supplementary Figure 1. Nested PCR for detection of F. psychrophilum in colonies recovered from 450 
moribund/mortalities post-challenge. 1% agarose gel showing second round PCR products. M: Ladder, Lane1-451 
16: bacterial DNA recovered from fish, (-) negative control, (+): positive control. 452 
 453 
